The NICE recommendation coincided with Novo Nordisk’s third quarter results statement, which showed modest 3% growth for Saxenda in the first nine months of the year to DKK 4.2 billion ($661 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback